Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorDuke University

About this trial

The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer:

Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result?

Specimens that are collected for routine clinical care and harbor Neisseria gonorrhoeae will be evaluated in this study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Be N. gonorrhoeae-positive on an FDA-cleared molecular assay

Have sufficient N. gonorrhoeae-positive specimen volume for testing using the corresponding investigational reflex test and genetic sequencing

Undergo proper handling and storage conditions

Disqualifiers

The N. gonorrhoeae-positive specimen media is not compatible with the investigational reflex test(s) at the laboratory site

The N. gonorrhoeae-positive specimen is not clearly labeled by the laboratory to link to basic epidemiologic data (age, sex) and source

Trial population

Clinical specimens from male and females that test positive for Neisseria gonorrhoeae

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

  • Investigational Reflex Test 1

    Diagnostic test

    Investigational Reflex Test 1

  • Investigational Reflex Test 2

    Diagnostic test

    Investigational Reflex Test 2

  • Investigational Reflex Test 3

    Diagnostic test

    Investigational Reflex Test 3

Treatment groups

3,291 Participants
are divided into 3 treatment groups
Group A: Urine3 interventions
Group B: Vaginal Swab3 interventions
Group C: Pharyngeal Swabs3 interventions

Trial outcomes

Primary outcomes

1

Number of participants with gyrA 91F identified by Investigational Reflex Test 1 relative to the sequenced results in urine

Investigational Reflex Test 1 results include gyrA 91F, gyrA 91S, invalid, and missing. Sanger Sequencing reference results include gyrA 91F, gyrA 91S, invalid, and missing.

Time frame
One day
2

Number of participants with gyrA 91F identified by Investigational Reflex Test 1 relative to the sequenced results in vaginal swabs

Investigational Reflex Test 1 results include gyrA 91F, gyrA 91S, invalid, and missing. Sanger Sequencing reference results include gyrA 91F, gyrA 91S, invalid, and missing.

Time frame
One day
3

Number of participants with gyrA 91F identified by Investigational Reflex Test 1 relative to the sequenced results in pharyngeal swabs

Investigational Reflex Test 1 results include gyrA 91F, gyrA 91S, invalid, and missing. Sanger Sequencing reference results include gyrA 91F, gyrA 91S, invalid, and missing.

Time frame
One day
4

Number of participants with gyrA 91F identified by Investigational Reflex Test 2 relative to the sequenced results in urine

Investigational Reflex Test 2 results include gyrA 91F, gyrA 91S, invalid, and missing. Sanger Sequencing reference results include gyrA 91F, gyrA 91S, invalid, and missing.

Time frame
One day

Secondary outcomes

1

Number of invalid results for Investigational Reflex Test 1 in urine

Time frame
One day
2

Number of invalid results for Investigational Reflex Test 1 in vaginal swabs

Time frame
One day
3

Number of invalid results for Investigational Reflex Test 1 in pharyngeal swabs

Time frame
One day
4

Number of invalid results for Investigational Reflex Test 2 in urine

Time frame
One day

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Duke University

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator

SpeeDx Pty Ltd

Collaborator

Abbott

Collaborator

Seegene USA Inc

Collaborator